Antonis C Antoniou

List of Publications by Citations

199 papers	15,480 citations	62 h-index	122 g-index
213 ext. papers	19,789 ext. citations	10 avg, IF	5.43 L-index

#	Paper	IF	Citations
199	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2402-2416	27.4	1140
198	Polygenic susceptibility to breast cancer and implications for prevention. *Nature Genetics*, **2002**, 31, 33-6	36.3	780
197	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
196	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *Journal of the National Cancer Institute*, **2013**, 105, 812-22	9.7	616
195	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587
194	Breast-cancer risk in families with mutations in PALB2. *New England Journal of Medicine*, **2014**, 371, 497-506	59.2	576
193	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 1748-57	2.2	440
192	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
191	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
190	Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nature Genetics*, **2011**, 43, 879-882	36.3	379
189	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
188	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
187	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	239
186	Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. *Genetic Epidemiology*, **2001**, 21, 1-18	2.6	234
185	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
184	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
183	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209

182	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
181	Polygenic inheritance of breast cancer: Implications for design of association studies. *Genetic Epidemiology*, **2003**, 25, 190-202	2.6	197
180	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *European Urology*, **2015**, 68, 186-93	10.2	192
179	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192
178	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
177	Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nature Genetics*, **2012**, 44, 475-6; author reply 476	36.3	190
176	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
175	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 404-412	4	185
174	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
173	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
172	Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). *Journal of the National Cancer Institute*, **2006**, 98, 535-44	9.7	161
171	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
170	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
169	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
168	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
167	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
166	Risk models for familial ovarian and breast cancer. *Genetic Epidemiology*, **2000**, 18, 173-90	2.6	128
165	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genetic Epidemiology*, **2005**, 29, 1-11	2.6	127

164	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Research*, **2007**, 9, 104	8.3	121
163	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Journal of Clinical Oncology*, **2013**, 31, 3091-9	2.2	118
162	Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. *Journal of Clinical Oncology*, **2007**, 25, 3831-6	2.2	116
161	Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Research*, **2006**, 66, 1866-72	10.1	111
160	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 601-10	4	110
159	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
158	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
157	Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes , and. *Journal of Medical Genetics*, **2018**, 55, 384-394	5.8	97
156	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
155	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. *Journal of the National Cancer Institute*, **2018**, 110, 714-725	9.7	92
154	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
153	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
152	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90
151	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
150	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
149	The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. *Clinical Cancer Research*, **2008**, 14, 2861-9	12.9	77
148	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
147	Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. *Journal of Medical Genetics*, **2013**, 50, 360-7	5.8	76

146	Risk prediction models for familial breast cancer. *Future Oncology*, **2006**, 2, 257-74	3.6	72
145	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
144	Improving reporting standards for polygenic scores in risk prediction studies. *Nature*, **2021**, 591, 211-219	50.4	70
143	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
142	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
141	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. *Breast Cancer Research*, **2006**, 8, R3	8.3	64
140	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. *Genetics in Medicine*, **2016**, 18, 1190-1198	8.1	64
139	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. *Journal of Medical Genetics*, **2014**, 51, 98-107	5.8	62
138	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
137	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
136	Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 740-6	4	56
135	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
134	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Human Molecular Genetics*, **2016**, 25, 2256-2268	5.6	55
133	Incorporating tumour pathology information into breast cancer risk prediction algorithms. *Breast Cancer Research*, **2010**, 12, R28	8.3	54
132	Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2006**, 8, R72	8.3	54
131	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
130	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. *European Urology*, **2020**, 77, 24-35	10.2	53
129	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51

128	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
127	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
126	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
125	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. *Journal of Medical Genetics*, **2014**, 51, 108-13	5.8	47
124	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1121-9	4	46
123	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. *Endocrine-Related Cancer*, **2016**, 23, T69-84	5.7	46
122	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
121	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
120	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. *Molecular Psychiatry*, **2020**, 25, 2392-2409	15.1	45
119	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
118	A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. *Journal of Medical Genetics*, **2015**, 52, 465-75	5.8	43
117	Specifying the ovarian cancer risk threshold of premenopausal risk-reducing salpingo-oophorectomy for ovarian cancer prevention: a cost-effectiveness analysis. *Journal of Medical Genetics*, **2016**, 53, 591-9	5.8	40
116	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. *American Journal of Obstetrics and Gynecology*, **2017**, 217, 578.e1-578.e12	6.4	39
115	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
114	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
113	Assessing and managing breast cancer risk: clinicians current practice and future needs. *Breast*, **2014**, 23, 644-50	3.6	33
112	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
111	Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genetic Epidemiology*, **2012**, 36, 274-91	2.6	33

110	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
109	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
108	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. *Genetics in Medicine*, **2017**, 19, 30-35	8.1	31
107	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
106	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nature Communications*, **2020**, 11, 3833	17.4	31
105	Current detection rates and time-to-detection of all identifiable carriers in the Greater London population. *Journal of Medical Genetics*, **2018**, 55, 538-545	5.8	30
104	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *Journal of Medical Genetics*, **2018**, 55, 546-554	5.8	30
103	Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. *Breast Cancer Research*, **2010**, 12, R10	8.3	27
102	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
101	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
100	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
99	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
98	iPrevent : a tailored, web-based, decision support tool for breast cancer risk assessment and management. *Breast Cancer Research and Treatment*, **2016**, 156, 171-82	4.4	25
97	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
96	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. *Journal of Medical Genetics*, **2018**, 55, 97-103	5.8	24
95	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. *Oncologist*, **2016**, 21, 716-22	5.7	24
94	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). *Breast Cancer Research*, **2018**, 20, 132	8.3	24
93	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. *American Journal of Obstetrics and Gynecology*, **2018**, 218, 431.e1-431.e12	6.4	23

92	Rare coding variants and X-linked loci associated with age at menarche. *Nature Communications*, **2015**, 6, 7756	17.4	23
91	Common genetic variants and cancer risk in Mendelian cancer syndromes. *Current Opinion in Genetics and Development*, **2010**, 20, 299-307	4.9	23
90	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2020**, 22, 8	8.3	22
89	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
88	Risk Prediction Models for Colorectal Cancer Incorporating Common Genetic Variants: A Systematic Review. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1580-1593	4	21
87	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
86	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. *Journal of Medical Genetics*, **2019**, 56, 347-357	5.8	19
85	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. *PLoS ONE*, **2020**, 15, e0229999	3.7	19
84	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genetics in Medicine*, **2020**, 22, 1803-1811	8.1	17
83	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
82	The BRCA2 c.68-7T□□A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
81	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
80	Homeobox B13 G84E Mutation and Prostate Cancer Risk. *European Urology*, **2019**, 75, 834-845	10.2	16
79	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
78	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *European Journal of Human Genetics*, **2017**, 25, 432-438	5.3	15
77	Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. *European Journal of Human Genetics*, **2014**, 22, 1330-3	5.3	15
76	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
75	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 44-56	7.1	15

74	CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. *Cancer Epidemiology Biomarkers and Prevention* , **2021**, 30, 469-473	4	14
73	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
72	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). *Journal of Personalized Medicine*, **2021**, 11,	3.6	13
71	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. *Australian Journal of Primary Health*, **2016**, 22, 255-261	1.4	13
70	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. *JNCI Cancer Spectrum*, **2018**, 2, pky023	4.6	13
69	A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 549-557	4	12
68	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. *Genetics in Medicine*, **2018**, 20, 1575-1582	8.1	12
67	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
66	Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1018-24	4	12
65	Chromatin interactome mapping at 139 independent breast cancer risk signals. *Genome Biology*, **2020**, 21, 8	18.3	12
64	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
63	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. *Breast Cancer Research*, **2021**, 23, 22	8.3	12
62	Non-coding RNAs underlie genetic predisposition to breast cancer. *Genome Biology*, **2020**, 21, 7	18.3	11
61	RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
60	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. *JNCI Cancer Spectrum*, **2018**, 2, pky078	4.6	10
59	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
58	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 368-378	4	9
57	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. *American Journal of Obstetrics and Gynecology*, **2021**, 225, 51.e1-51.e17	6.4	9

56	Breast cancer risk in women with PALB2 mutations in different populations. *Lancet Oncology, The*, **2015**, 16, e375-6	21.7	8
55	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. *Cancers* , **2020**, 12,	6.6	8
54	Clinical software development for the Web: lessons learned from the BOADICEA project. *BMC Medical Informatics and Decision Making*, **2012**, 12, 30	3.6	8
53	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. *JNCI Cancer Spectrum*, **2019**, 3, pkz066	4.6	7
52	Cancer Risks Associated With and Pathogenic Variants.. *Journal of Clinical Oncology*, **2022**, JCO2102112	2.2	7
51	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
50	Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 220-226	2.7	7
49	The future of early cancer detection.. *Nature Medicine*, **2022**, 28, 666-677	50.5	7
48	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. *Familial Cancer*, **2018**, 17, 31-41	3	6
47	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
46	pedigreejs: a web-based graphical pedigree editor. *Bioinformatics*, **2018**, 34, 1069-1071	7.2	5
45	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. *Journal of Medical Genetics*, **2021**,	5.8	5
44	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. *JMIR Formative Research*, **2018**, 2, e24	2.5	5
43	CliniciansQuse of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. *Journal of Community Genetics*, **2019**, 10, 61-71	2.5	5
42	External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank. *Cancer Prevention Research*, **2020**, 13, 509-520	3.2	4
41	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2021**, 113, 893-899	9.7	4
40	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
39	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. *BJU International*, **2021**,	5.6	4

38	Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate. *Cancers*, **2020**, 12,	6.6	3
37	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
36	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. *JNCI Cancer Spectrum*, **2021**, 5, pkab021	4.6	3
35	Potential of polygenic risk scores for improving population estimates of women breast cancer genetic risks. *Genetics in Medicine*, **2021**, 23, 2114-2121	8.1	3
34	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
33	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. *Journal of Personalized Medicine*, **2021**, 11,	3.6	3
32	Prostate Cancer Risk by BRCA2 Genomic Regions. *European Urology*, **2020**, 78, 494-497	10.2	2
31	Letter to the editor: a response to Ming study on machine learning techniques for personalized breast cancer risk prediction. *Breast Cancer Research*, **2020**, 22, 17	8.3	2
30	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. *Genetics in Medicine*, **2021**,	8.1	2
29	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors		2
28	Immune Cell Associations with Cancer Risk. *IScience*, **2020**, 23, 101296	6.1	2
27	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
26	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. *Genetics in Medicine*, **2021**,	8.1	2
25	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1
24	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. *Journal of the National Cancer Institute*, **2022**,	9.7	1
23	Predicting the Likelihood of Carrying a or Mutation in Asian Patients With Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101647	2.2	1
22	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. *Journal of Clinical Oncology*, **2013**, 31, e20660-e20660	2.2	1
21	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. *Journal of Clinical Oncology*, **2013**, 31, 17-17	2.2	1

20	Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer.. *Journal of Clinical Oncology*, **2013**, 31, 29-29	2.2	1
19	Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses. *Npj Breast Cancer*, **2021**, 7, 46	7.8	1
18	Characterisation of protein-truncating and missense variants in in 15 768 women from Malaysia and Singapore. *Journal of Medical Genetics*, **2021**,	5.8	1
17	Risk models for familial ovarian and breast cancer **2000**, 18, 173		1
16	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. *Diagnostics*, **2022**, 12, 1028	3.8	1
15	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. *Cancers*, **2022**, 14, 2716	6.6	1
14	Segregation analysis of 17,425 population-based breast cancer families: evidence for genetic susceptibility and risk prediction		1
13	Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. *Human Mutation*, **2021**, 42, 1488-1502	4.7	0
12	Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.. *BMC Medicine*, **2022**, 20, 150	11.4	0
11	Reply to V. Fallet et al.. *Journal of Clinical Oncology*, **2022**, JCO2200782	2.2	0
10	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention.. *Preventive Medicine*, **2022**, 107075	4.3	0
9	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study.. *Journal of Clinical Oncology*, **2017**, 35, 1558-1558	2.2	
8	BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 1545-1545	2.2	
7	Profile study: Genetic prostate cancer risk stratification for targeted screening.. *Journal of Clinical Oncology*, **2013**, 31, 5054-5054	2.2	
6	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. *Journal of Clinical Oncology*, **2013**, 31, 1559-1559	2.2	
5	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.. *Journal of Clinical Oncology*, **2014**, 32, 22-22	2.2	
4	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		
3	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		

List of Publications

2 Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999

1 Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999